It has been discovered that sleeping pills lower levels of Alzheimer's proteins.

Published Date: 26 Apr 2023

Sleep issues may be a precursor to Alzheimer's disease. Many people who are eventually diagnosed with Alzheimer's have trouble falling and staying asleep years before they develop cognitive issues like memory loss.

Read Full News

Latest News

AI Model Distinguishes EDSS Subgroup Patterns in Multiple Sclerosis, Study Shows Louie Pasculli

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes Marco Meglio

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines Benjamin Greenberg, MD, Louie Pasculli

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

NeurologyLive® Brain Games: January 4, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!

Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS Marco Meglio

ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.

Todays Updates

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis Marco Meglio

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Pulmonology in 2025: Year in Review

Pulmonology in 2025: Year in Review

Q4 2025 Recap: Pulmonology News and Updates

Q4 2025 Recap: Pulmonology News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Todays Updates

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis Marco Meglio

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Pulmonology in 2025: Year in Review

Pulmonology in 2025: Year in Review

Q4 2025 Recap: Pulmonology News and Updates

Q4 2025 Recap: Pulmonology News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Latest News

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

Here's some of what is coming soon to NeurologyLive® this week.

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!

ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.

News All Time

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

NeurologyLive® Brain Games: December 28, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination Kevin Chang, PharmD

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

NeurologyLive® Year in Review 2025: Top Podcast Episodes Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.

Episode 157: Clinical Advances and Unanswered Questions in Narcolepsy Marco Meglio, Lindsay McCullough, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lindsay McCullough, MD. [LISTEN TIME: 14 minutes]

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Recommended News For You

Video: Liver transplant for patients with advanced colorectal cancer

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

Studies point to redlining as a 'perfect storm' for breast cancer

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.

Recommended Articles For You

Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025 

Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options 

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells 

Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Insurance Claim Denials for Preventive Care More Common in At-Risk Patients

2.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

3.

A Lot Can Be Said About You by Including Yourself in Photos.

4.

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

5.

Study finds higher breast cancer rates in areas with more air pollution

1.

Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy

2.

Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide 

3.

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer

4.

Managing Acute Respiratory Failure in Hematological Malignancies

5.

Exploring the Role of Fecal Leukocytes in Intestinal Health

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part II

2.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

3.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot